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Abstract 
As part of its single technology appraisal (STA) process, the National Institute for Health and Care 
Excellence (NICE) invited the manufacturer (Pfizer) of tofacitinib (TOF; Xeljanz®) to submit evidence 
of its clinical and cost-effectiveness for the treatment of rheumatoid arthritis (RA) after the failure of 
conventional disease-modifying anti-rheumatic drugs (cDMARD). The School of Health and Related 
Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the 
independent Evidence Review Group (ERG). The ERG produced a detailed review of the evidence for 
the clinical and cost-HIIHFWLYHQHVVRIWKHWHFKQRORJ\EDVHGXSRQWKHFRPSDQ\¶VVXEPLVVLRQWR1,&(
The clinical effectiveness evidence in the comSDQ\¶VVXEPLVVLRQIRUTOF is based predominantly on 
four randomised controlled trials (RCTs) comparing the efficacy of TOF against placebo. Three RCTs 
investigated TOF in combination with methotrexate (MTX) and one RCT investigated TOF 
monotherapy. All four RCTs compared TOF with placebo plus cDMARDs, one RCT also included 
adalimumab as a comparator. The study population in the four RCTs comprised patients who were 
MTX or cDMARD inadequate responders (cDMARD-IR). The company performed network meta-
analyses (NMA) to assess the relative efficacy of TOF compared with biologic disease-modifying 
antirheumatic drugs (bDMARD) in patients who were inadequate responders (IR) to conventional 
DMARDs (cDMARD-IR) or to biologic DMARDs (bDMARD±IR) with moderate-to-severe RA for 
EULAR response and change in the Health Assessment Questionnaire disability index (HAQ-DI) at 6 
months7KHFRPSDQ\¶V10$FRQFOXGHGWKDWTOF had comparable efficacy to bDMARDs currently 
recommended by NICE. The company submitted a de novo model that assessed the cost effectiveness 
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of TOF versus its comparators in six different populations: (i) cDMARD-IR patients with severe RA; 
(ii) cDMARD-IR patients with severe RA for whom MTX is contraindicated or not tolerated; (iii) 
patients who are bDMARD-IR; (iv) patients who are bDMARD-IR for whom rituximab (RTX) is 
contraindicated or not tolerated; (v) patients who are bDMARD-IR for whom MTX is contraindicated 
or not tolerated; and, (vi) cDMARD-IR patients with moderate RA. $FFRUGLQJ WR WKH FRPSDQ\¶s 
economic analyses, in cDMARD-IR patients with severe RA, TOF plus MTX dominates or extendedly 
dominates most comparators whilst TOF monotherapy is slightly less effective and less expensive than 
its comparators with the cost saved per quality-adjusted life year (QALY) lost always higher than 
£50,000. In bDMARD-IR patients with severe RA, RTX plus MTX dominated TOF plus MTX but in 
patients for whom RTX was not an option, TOF plus MTX dominated all comparators included in the 
analysis (four comparators recommended by NICE were not included). In cDMARD-IR patients with 
moderate RA, the cost per QALY for TOF in combination with MTX or as monotherapy compared 
with a sequence of cDMARDs was estimated to be greater than £50,000 per QALY. The ERG identified 
a QXPEHURIOLPLWDWLRQVLQWKHFRPSDQ\¶VDQDO\VHV, including use of a fixed-effects model in the NMA 
and the use of treatment sequences in the cost-effectiveness model which did not reflect NICE 
recommendations. These limitations were addressed partly by the company during the clarification 
round and partly by the ERG. The exploratory analyses undertaken by the ERG resulted in similar 
conclusions: (i) TOF plus MTX was dominated by RTX plus MTX; (ii) TOF in combination with MTX 
or as monotherapy dominates or extendedly dominates some of its comparators in cDMARD-IR and 
bDMARD-IR patients with severe RA for whom RTX plus MTX was not an option; and (iii) in 
cDMARD-IR patients with moderate RA, the cost per QALY of TOF in combination of MTX or as a 
monotherapy versus cDMARDs was in excess of £47,000. 
The NICE Appraisal Committee consequently recommended TOF plus MTX as an option for patients 
whose disease has responded inadequately to intensive therapy with a combination of cDMARDS only 
if i.) disease is severe (a disease activity score [DAS28] of more than 5.1) and ii.) the company provides 
TOF with the discount agreed in the patient access scheme (PAS). TOF plus MTX is also recommended 
as an option for adults whose disease has responded inadequately to, or who cannot have, other 
DMARDs, including at least 1 bDMARD, only if: i.) disease is severe and, ii.) they cannot have RTX 
and, iii) the company provides TOF with the discount agreed in the PAS. For patients who are intolerant 
of MTX, or where MTX is contraindicated TOF monotherapy is recommended where TOF plus MTX 
would be recommended.   
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Key points for decision makers 
x Tofacitinib (TOF) plus methotrexate (MTX) has shown similar clinical efficacy and 
comparable costs to other recommended biologic disease-modifying antirheumatic drugs 
(bDMARD) plus MTX in patients with rheumatoid arthritis (RA). 
 
x In patients who have had an inadequate response to bDMARDs and who are eligible for 
rituximab (RTX) in combination with MTX, RTX plus MTX is of similar clinical efficacy to 
TOF plus MTX but has a significantly lower cost. Therefore, RTX plus MTX should be 
preferred to TOF plus MTX. 
 
x In patients who have had an inadequate response to conventional disease-modifying 
antirheumatic drugs (cDMARD-IR) for whom MTX is contraindicated or not tolerated, TOF 
monotherapy has a similar efficacy and comparable costs to bDMARD monotherapies 
recommended by NICE in this population. There is no available evidence to compare the 
effectiveness of TOF monotherapy to that of recommended bDMARD mono therapies in 
bDMARD-IR patients. 
 
x The relative simplicity of the decision when bDMARDs were the main comparator provides 
supportive evidence that fast-track appraisals which have been proposed by NICE where 
efficacy and costs are comparable can be delivered. 
 
1. Introduction 
The National Institute for Health and Care Excellence (NICE) is an independent organisation 
responsible for providing national guidance on promoting good health and preventing and treating ill 
health in priority areas with significant impact. Health technologies must be shown to be clinically 
effective and to represent a cost-effective use of National Health Service (NHS) resources in order for 
NICE to recommend their use within the NHS in England. The NICE Single Technology Appraisal 
(STA) process usually covers new single health technologies within a single indication, soon after their 
UK market authorisation [1]. Within the STA process, the company provides NICE with a written 
VXEPLVVLRQDORQJVLGHDPDWKHPDWLFDOPRGHOWKDWVXPPDULVHVWKHFRPSDQ\¶VHVWLPDWHVRIWKHFOLQLFDO
and cost effectiveness of the technology. This submission is reviewed by an external organisation 
independent of NICE (the Evidence Review Group [ERG]), which consults with clinical specialists and 
SURGXFHVD UHSRUW$IWHUFRQVLGHUDWLRQRI WKHFRPSDQ\¶V VXEPLVVLRQ WKH(5*UHSRUWDQG WHVWLPRQ\
from experts and other stakeholders, the NICE Appraisal Committee (AC) formulates preliminary 
guidance, the Appraisal Consultation Document (ACD), which indicates the initial decision of the AC 
4 
 
regarding the recommendation (or not) of the technology. Stakeholders are then invited to comment on 
the submitted evidence and the ACD, after which a further ACD may be produced or a Final Appraisal 
Determination (FAD) issued, which is open to appeal. An ACD is not produced when the technology 
is recommended within its full marketing authorisation; in this case, a FAD is produced directly. 
 
This paper presents a summary of the ERG report[2] for the STA of tofacitinib (TOF; Xeljanz®) in 
combination with methotrexate (MTX) for treating rheumatoid arthritis (RA) for patients whose disease 
has responded inadequately to at least one conventional biologic disease-modifying antirheumatic drugs 
(cDMARD) or biologic DMARD (bDMARD) and TOF as monotherapy in case of intolerance to MTX 
or when treatment with MTX is inappropriate. The paper includes a summary of the subsequent 
development of the NICE guidance for the use of this technology in England. Full details of all relevant 
appraisal documents (including the appraisal scope, ERG report, company and consultee submissions, 
FAD and comments from consultees) can be found on the NICE website.[3] 
 
2. The Decision Problem 
RA is a chronic inflammatory disease characterised by: progressive, irreversible, joint damage; 
impaired joint function; pain and tenderness caused by swelling of the synovial lining of joints.[4] 
The condition is associated with increasing disability and reduced quality of life.[4] The primary 
symptoms are pain; morning stiffness; swelling; tenderness; loss of movement; redness of the 
peripheral joints; and fatigue.[5, 6] RA is associated with substantial costs both directly (associated 
with drug acquisition and hospitalisation) and indirectly due to reduced productivity.[7] RA has long 
been reported as being associated with increased mortality,[8, 9] particularly due to cardiovascular 
events.[10] NICE estimates that there are 400,000 patients in the UK with RA,[11] based on a 
prevalence of 0.8% reported by Symmons et al.[12] The incidence of RA is greater in females (3.6 
per 100,000 per year) than in males (1.5 per 100,000 per year).[13] For both genders, the peak age of 
incidence in the UK is in the eighth decade of life, but all ages can develop the disease.[13]  
 
Two classifications have dominated the measurement of improvement in RA symptoms: American 
College of Rheumatology (ACR) responses[14] and European League Against Rheumatism (EULAR) 
responses.[15] ACR response has been widely adopted in randomised controlled trials (RCTs) although 
studies have shown that the value of the measure can vary between studies due to the timing of the 
response.[16]  In the UK, monitoring the progression of RA is often undertaken using the disease 
activity score of 28 joints (DAS28). The DAS28 can be used to classify both the disease activity of the 
patient and the level of improvement estimated within the patient. The EULAR response criteria use 
the individual change in DAS28 and the absolute DAS28 score to classify a EULAR response as good, 
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moderate or none. [15] EULAR response has been reported less frequently in RCTs than ACR 
responses.[17] However, EULAR response is much more closely aligned to the treatment continuation 
rules stipulated by NICE, which require either a moderate or good EULAR response or a DAS28 
improvement of more than 1.2 to continue treatment with bDMARDs.  
 
2.1 Current Treatment 
For patients with newly diagnosed RA, NICE recommends considering a combination of cDMARDs, 
including MTX and at least one other cDMARD plus short-term glucocorticoids, as first-line treatment, 
ideally beginning within 3 months of the onset of persistent symptoms.[11]  NICE currently 
recommends the use of the following bDMARDs: baricitinib (BARI); abatacept (ABA); adalimumab 
(ADA); certolizumab pegol (CZP); etanercept (ETA); golimumab (GOL); infliximab (IFX); and 
tocilizumab (TCZ) each in combination with MTX for patients who have severe active RA (defined as 
a DAS28 score greater than 5.1) after the failure to respond to cDMARD treatment. For patients who 
meet these criteria but for whom MTX is contraindicated or has been withdrawn, NICE recommends 
the use of ADA, CZP, ETA and TCZ as monotherapy.[18] Most of these bDMARDs (all except BARI, 
ABA and TCZ) are TNFis. After the failure of the first TNFi, NICE recommends rituximab (RTX) in 
combination with MTX for the treatment of severe active RA.[19] If RTX is contraindicated or 
withdrawn because of an adverse event (AE), NICE recommends ABA, ADA, BARI, CZP, ETA, GOL, 
IFX or TCZ in combination with MTX [18, 20, 21]. If MTX is contraindicated or withdrawn because 
of an AE, NICE recommends ADA or ETA[22] as monotherapy. NICE also recommends TCZ in 
combination with MTX as a third line biologic after inadequate response to RTX in combination with 
MTX.[20] 
Treatment continuation criteria vary across TAs: TA375[19]  states that for patients to continue 
treatment with their first bDMARD treatment they must achieve and maintain at least a moderate 
EULAR response. For RTX, TA195[23] states that treatment should be continued only if there is an 
improvement in the DAS28 score of at least 1.2 points at initiation of treatment and whilst this response 
is maintained. If the relevant continuation criterion is not met, then the treatment should be stopped and 
the next treatment in the sequence initiated.  
3. The Independent ERG Review 
In accordance with the process for STAs, the ERG and NICE had the opportunity to seek clarification 
RQVSHFLILFSRLQWVLQWKHFRPSDQ\¶VVXEPLVVLRQ&6[24] in response to which the company provided 
DGGLWLRQDOLQIRUPDWLRQ7KH(5*DOVRPRGLILHGWKHFRPSDQ\¶VGHFLVLRQDQDO\WLFPRGHOWRSURGXFHDQ
ERG base case and to assess the impact of alternative parameter values and assumptions on the model 
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UHVXOWV7KHHYLGHQFHSUHVHQWHGLQWKHFRPSDQ\¶VVXEPLVVLRQDQGWKH(5*¶VUHYLHZRIWKDWHYLGHQFHLV
summarised here. 
 
3.1 Clinical Evidence Provided by the Company 
Evidence was presented in the CS for the efficacy of TOF in combination with MTX and other 
cDMARDs or as monotherapy in the treatment of moderate to severe RA in patients after the failure of 
disease-modifying anti-rheumatic drugs (DMARDs). This evidence was based primarily on four RCTs 
(ORAL Standard[25], ORAL Scan[26] and ORAL Sync[27] for TOF plus MTX; ORAL Solo for TOF 
monotherapy[28]). MTX plus placebo was the comparator in ORAL Scan and ORAL Sync; placebo 
without MTX was the comparator in ORAL Solo; and an active treatment (ADA) and placebo were the 
comparators in ORAL Standard. In addition to treatment groups receiving the licenced dose of TOF at 
5 mg twice daily, all four RCTs also included treatment groups receiving tofacitinib 10 mg twice daily 
(a currently unlicensed dose). Preliminary results were also provided for a recently completed, head-to-
head trial (ORAL Strategy) of TOF plus MTX vs ADA plus MTX vs TOF monotherapy. 
The population in ORAL Standard and ORAL Scan related to adults with active moderate-to-severe 
RA who were cDMARD experienced and MTX-IR. The population in ORAL Sync and ORAL Solo 
was adults with active moderate-to-severe RA who were DMARD inadequate responders (DMARD-
IR) ORAL Solo had a 24-week randomised period, ORAL Standard and ORAL Sync had a 52-week 
randomised period and ORAL Scan had a 104-week randomised period. In ORAL Standard, ORAL 
Scan and ORAL Sync, patients receiving placebo advanced to TOF 5 mg at month 3 if trial response 
criteria were not met (defined as a 20% reduction in the number of tender and swollen joints). A co-
primary outcome for ORAL Standard, ORAL Scan and ORAL Sync was the proportion of patients 
achieving an ACR20 response at six months. A co-primary outcome for ORAL Solo was the 
proportion of patients achieving an ACR20 response at three months. The primary endpoint for the 
ORAL Strategy trial was ACR50 response at 6 months. Other relevant endpoints in the included trials 
included the proportion of patients achieving low disease activity at 3 and 6 months, and the 
proportion of patients achieving disease remission at 3 months using the Disease Activity Score 28 
outcome (DAS28). 
Using the co-primary outcome of ACR20, the three trials of TOF plus MTX showed TOF 5 mg twice 
daily plus methotrexate to be statistically superior to placebo plus cDMARD (p at 6 months. 
Other statistically significant results (pwere demonstrated across these trials versus placebo for 
ACR50, ACR70, and treatment response using EULAR criteria and Health Assessment Questionnaire 
Disability Index (HAQ-DI) at both 3 and 6 months with the following exceptions: 
(i) the proportion achieving disease remission using DAS28(ESR) in ORAL Scan at 6 months 
when using the stepdown statistical approach;  
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(ii) the change in baseline HAQ-DI in ORAL Scan at 6 months when using the step-down statistical 
approach. 
ACR20 was significant for TOF monotherapy versus placebo at 3 months in one trial (ORAL Solo) 
but not significant for the primary endpoint of the proportion achieving remission using DAS28(ESR) 
at 3 months. As all patients crossed over from placebo to receive TOF at 3 months in ORAL Solo, 
there are no placebo-controlled results at 6 months for the other relevant endpoints. The ORAL 
Strategy trial showed TOF combination therapy with methotrexate to be non-inferior to ADA plus 
MTX (<0.0001) but TOF monotherapy was not found to be non-inferior to both TOF plus MTX and 
ADA plus MTX for the primary endpoint of ACR50 at 6 months (p=0.0512). 
A revised summary of safety data for TOF provided by the company following an ERG request showed 
that the highest incidence rates of AEs were for serious infection events and herpes zoster. Additional 
data provided by the company indicated bronchitis, pneumonia and all cardiac disorders occurred most 
commonly in the TOF treatment arms.  
 
Network meta-analyses (NMA) were performed to assess the relative efficacy of TOF compared with 
the comparators in patients who were inadequate responders (IR) to conventional DMARDs 
(cDMARD-IR) or to biologic DMARDs (bDMARD±IR) with moderate-to-severe RA for EULAR 
response and change in the HAQ-DI at 6 months. For the base case NMA cDMARD-IR population, the 
odds of achieving a EULAR response were all statistically higher for tofacitinib in combination with 
methotrexate (TOF plus cDMARD) compared to cDMARD at 6 months. No statistically significant 
differences were found for TOF plus cDMARD versus bDMARDs plus cDMARD, except for TOC 
plus cDMARD, which was statistically superior in attaining at least a good EULAR response. 
 
Whilst the odds of all EULAR responses were higher in TOF monotherapy compared to cDMARD, 
only the effect for a good response was statistically significant. No statistically significant differences 
were found in TOF versus bDMARDs. Both TOF plus cDMARD and TOF monotherapy were 
associated with significant reduction in HAQ-DI compared with cDMARD at 6 months. 
 
For the base case NMA bDMARD-IR population, the odds of all EULAR responses were all statistically 
higher in TOF plus cDMARD compared with cDMARD at 6 months. No statistically significant 
differences were found for TOF plus cDMARD versus abatacept (ABT) plus cDMARD. TOF plus 
cDMARD was statistically superior compared to golimumab (GOL) plus cDMARD in attaining both 
at least a moderate and a good EULAR response; but statistically inferior versus RTX plus cDMARD, 
TOF plus cDMARD, non-tumour necrosis factors alpha inhibitors (non-TNFi) plus cDMARD and 
TNFi plus cDMARD. TOF in combination with cDMARD was associated with a significant reduction 
in HAQ-DI compared with cDMARD at 6 months. 
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3.1.1 Critique of the Clinical Evidence and Interpretation 
The eligibility criteria applied in the selection of evidence for the clinical effectiveness review were 
considered by the ERG to be reasonable and generally consistent with the decision problem as 
outlined in the final NICE scope. 
Whilst the ERG considered WKHFRPSDQ\¶VOLWHUDWXUHVHDUFKHVto be sufficient and comprehensive to 
retrieve relevant and up-to-date data for clinical effectiveness, the searches for safety data were not 
sufficient to identify all up-to-date relevant AE data for TOF. 7KH&6UHSRUWHGWKDWD³GDWDFXW´ZDV
imposed on the safety data such that only trials included in the published pooled analysis,[29] which 
included trial data up to March 2015, were included in the safety overview. In a response to ERG 
clarification the company confirmed that a separate search for AEs was not undertaken and that data 
on AEs were identified as part of a broader search of efficacy, safety and health-related quality of life. 
The ERG noted that pooling safety data across all trials and providing incidence rates may be 
inappropriate to fully document the potentially different safety profiles of TOF combination therapy 
with MTX versus TOF monotherapy. 7KH(XURSHDQ3XEOLF$VVHVVPHQW5HSRUWKLJKOLJKWHG³a 
higher incidence of adverse events for the combination of Xeljanz with MTX, compared with Xeljanz 
as monotherapy´DQGWKDW³combination of tofacitinib with methotrexate increased the risk of ALT 
[alanine transaminase] elevation compared with tofacitinib monotherapy´ [30] 
The quality of the included RCTs for TOF were assessed using well established and recognised criteria. 
Data for extra-articular manifestations of disease were not included in the CS. Mortality data were 
SUHVHQWHGIRU³GHDWKZithin 30 days of last dose of study drug´LQWKHSRROHGVDIHW\DQDO\VLV 
Network meta analyses (NMA) were performed separately for both the cDMARD- IR and bDMARD- 
IR population using a Bayesian approach for EULAR response at month 6 and change from baseline 
HAQ-DI score at month 6. Trials in the analysis of the cDMARD-IR population were largely the 
same as those in the NMA undertaken by the independent Assessment Group in NICE Technology 
Assessment (TA) 375.[19] A similar comparison could not be made for the bDMARD-IR population, 
as this was outside of the scope of TA375. 
The ERG believes that the results presented in NMA of clinical effectiveness should be treated with 
caution, as the ordered categorical EULAR data were dichotomised in the cDMARD-IR population, 
which ignores the natural ordering and correlations between the EULAR response categories. A fixed 
effects model was used in all the analyses in the bDMARD-IR population, and EULAR response 
(moderate response and good response) in the cDMARD-IR population. Heterogeneity is expected and 
this approach underestimates uncertainty in the treatment effects. For TOF trials with early escape, the 
results from non-responder imputation without advancement penalty (non-responder imputation only 
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applied for the placebo arm, not the TOF arm) were used in the base case NMAs. This imputation 
approach potentially overestimates the relative treatment effect of TOF in these trials. Depending on 
the non-responder imputation approach applied to the TOF trials with early escape, the conclusion for 
the efficacy ranking of TOF among the bDMARDs varies markedly. 
3.2 Cost-Effectiveness Evidence Provided by the Company 
The company supplied a de novo discrete event simulation model constructed in Microsoft Excel® that 
was largely based on the model developed by the assessment group in TA375.[19] The model simulates 
SDWLHQWV¶GLVHDVHSURJUHVVLRQs as they go through the sequences of treatments being compared. For each 
line of treatment, patients may achieve good, moderate or no EULAR response, which is assessed at 6 
months after treatment initiation. The EULAR response rates for TOF as a monotherapy or in 
combination with MTX are estimated using a regression model calculated based on TOF trial data. The 
EULAR response rates for the comparator treatments are calculated by applying odd ratios (ORs) based 
RQ WKH FRPSDQ\¶V 10$ to TOF response rates. Patients who achieve moderate or good EULAR 
response are assumed to have an improvement in HAQ-DI score and remain on treatment until loss of 
efficacy (as assessed by a clinician), AE occurrence or death. Time to treatment discontinuation for 
responders is estimated using survival curves fitted to TOF trial data using patient characteristics as 
predictive covariates. Patients who fail to achieve a moderate or good EULAR response at 6 months 
discontinue treatment and move on to the next treatment in the sequence. HAQ-DI is assumed to remain 
constant whilst on bDMARDs or TOF whilst for patients on cDMARDs and palliative care, HAQ-DI 
progression is assumed to be non-linear based on latent HAQ-DI trajectory classes.[31] Patients are 
assumed to experience an increase in HAQ-DI equal to the value of the decrease in HAQ-DI achieved 
on treatment initiation, with the increase occurring over the six months before treatment 
discontinuation, when the next treatment in the sequence is employed. The mortality rate is assumed to 
be affected by the SDWLHQW¶VHAQ-DI score at baseline but not by HAQ-DI progression. The model 
estimates the costs and quality-adjusted life years (QALYs) over a lifetime horizon from the perspective 
of the National Health Service (NHS) and Personal Social Services . Health-related quality of life was 
modelled using values from the EuroQol 5 Dimensions (EQ-5D) questionnaire. Changes in EQ-5D are 
estimated based on a mapping algorithm from HAQ-DI scores and patient characteristics. 
Hospitalisation costs and resource use estimates were based on HAQ-DI score bands as in NICE 
TA375,[19] with unit costs taken from the British National Formulary (BNF) [32] and NHS Reference 
Costs 2015/16.[33] A patient access scheme (PAS) for TOF had been agreed with the Department of 
Health.  
The analyses presented in the CS relate to six different populations of rheumatoid arthritis patients: (i) 
cDMARD-IR patients with severe RA that can tolerate MTX; (ii) cDMARD-IR patients with severe 
RA for whom MTX is contraindicated or not tolerated; (iii) patients who are bDMARD-IR, for whom 
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RTX is an option; (iv) patients who are bDMARD-IR and RTX ineligible; (v) patients who are 
bDMARD-IR for whom MTX is contraindicated or not tolerated; and, (vi) patients with moderate RA 
who are cDMARD-IR. Severe RA was defined as a DAS28 > 5.1, whilst moderate RA was defined as 
a DAS28 !DQG Baseline characteristics of patients are based on the relevant TOF studies. 
In the analyses presented by the company for cDMARD-IR patients with severe RA who could tolerate 
MTX, TOF plus MTX dominated or extendedly dominated the majority of bDMARD comparators; the 
incremental cost-effectiveness ratios (ICERs) of the remaining comparators were higher than £80,000 
per QALY gained. In cDMARD-IR patients with severe RA for whom MTX was contraindicated or 
not tolerated, TOF is less effective and less expensive than the recommended bDMARDs (ETA, ADA 
and TCZ) but the cost saved per QALY lost (southwest quadrant) is higher than £50,000. In bDMARD-
IR patients with severe RA for whom RTX was an option, RTX plus MTX dominated TOF plus MTX. 
In bDMARD-IR patients with severe RA for whom RTX is not an option, TOF plus MTX dominated 
all the comparators included in the analysis (although four recommended comparators were not 
included). In bDMARD-IR patients with severe RA for whom MTX was contraindicated or not 
tolerated, the ICER for TOF compared with TCZ was estimated to be £25,932 per QALY gained. 
However, TCZ monotherapy is not recommended by NICE in this population and none of the 
comparators recommended by NICE were included in the analysis. In cDMARD-IR patients with 
moderate RA, the ICER for TOF plus MTX compared with a sequence of cDMARD treatments was 
estimated to be £51,693 per QALY gained and the ICER for TOF monotherapy compared with a 
different sequence of cDMARDs was estimated to be £51,370 per QALY. All of the analyses presented 
excluded the commercial-in-confidence PASs in place for TCZ and ABT, as requested by NICE. 
The company presented additional analyses during the clarification round amending the NMA and 
incorporating the following corrections requested by the ERG: (i) amended sequences in line with 
TA375; (ii) using non-linear latent class HAQ-DI trajectories for palliative care, (iii) amended changes 
in HAQ-DI scores upon moderate or good EULAR response, (iv) use of age at onset instead of age as 
predictor of class membership for the latent class mixture model, and (v) the activation of the flag that 
establishes a patient as bDMARD-IR after going through their first bDMARD or Janus kinase inhibitor. 
The analyses undertaken with the revised model resulted in slightly different ICERs but did not modify 
the conclusions of the analyses included in the CS. 
3.2.1 Critique of the Cost-Effectiveness Evidence and Interpretation 
7KHFRPSDQ\¶VRULJLQDOHFRQRPLFDQDO\VLVFRQWDLQHGVHYHUDOLVVXHVWKHPRVWLPSRUWDQWEHLQJWKDWWKH
sequences used in the model did not appropriately reflect NICE recommendations: and, the model 
assumed a constant worsening of HAQ-DI instead of using the non-linear HAQ-DI trajectories observed 
by Norton et al.[31] The ERG communicated these shortcomings during the clarification round and the 
company presented new analyses after addressing these issues. 7KH(5*EHOLHYHVWKDWWKHFRPSDQ\¶V 
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revised analyses included a number of limitations. First, relevant comparators recommended by NICE 
were missLQJIURPWKHFRPSDQ\¶VDQDO\VHVin the analysis for bDMARD-IR MTX-intolerant patients 
with severe RA, all relevant comparators (ADA, ETN and CTZ as monotherapies) were missing and in 
the analysis for bDMARD-IR patients with severe RA who are RTX-ineligible four comparators (ADA, 
ETN, IFX and CTZ with concomitant MTX) were missing. The company justified these omissions 
citing the lack of evidence for the missing comparators in the relevant populations. Second, the 
FRPSDQ\¶V10$VXIIHUHGIURPDVHULHVRIOLPLWDWLRQVDVGHVFULEHGLQSection 3.1.1. For example, the 
treatment effect was estimated by applying a non-responder imputation (NRI) only in the placebo arm 
(estimate 1), instead of applying NRI in both arms (estimate 2). The ERG believes that the true treatment 
effect lies between these two estimates and that this uncertainty should have been explored in sensitivity 
analyses. Third, the company assumed TOF as monotherapy to have equal efficacy to TOF plus MTX 
in terms of moderate and good EULAR response rates. However, in the ORAL Strategy trial, [34] TOF 
monotherapy was not found to be non-inferior to TOF plus MTX and the results of the NMA show that 
TOF monotherapy results in slightly lower rates of response compared with TOF plus MTX. Fourth, 
the company assumed sulfasalazine to have the same efficacy as placebo in the analysis for the 
cDMARD-IR MTX-intolerant population. The ERG believes this leads to an underestimation of the 
efficacy of sulfasalazine . Finally, the company rounded modified HAQ-DI values to the nearest valid 
HAQ-DI score rather than allowing the valid HAQ-DI score to be sampled based on the continuous 
HAQ-DI value. The ERG notes that this approach might lead to inaccurate estimations of HAQ-DI 
scores, as values might be rounded up more often than they are rounded down or vice versa.  
3.3 Additional Work Undertaken by the ERG 
The ERG undertook additional analyses after applying two FKDQJHV WR WKH FRPSDQ\¶V PRGHO (i) 
calculating the ORs for all treatments including monotherapies compared to TOF+MTX instead of 
assuming TOF monotherapy to have the same efficacy as TOF plus MTX; and, (ii) sampling a valid 
HAQ-DI score based on the modified HAQ-DI score as in TA375.[19]  The ERG undertook two sets 
of analyses for each populatLRQRQHEDVHGRQ WKHFRPSDQ\¶V10$DQGWKHRWKHURQHEDVHGRQWKH
NMA requested by the ERG (referred to as clarification NMA) addressing the issues described in 
Section 3.1.1. and applying NRI in both arms. The results presented here do not include the confidential 
PASs in place for TCZ and ABT. 
For cDMARD-,5SDWLHQWVZLWKVHYHUH5$ZKRFDQWROHUDWH07;EDVHGRQWKHFRPSDQ\¶V10$TOF 
plus MTX dominated all bDMARD comparators except ETA biosimilar + MTX. Based on the 
clarification NMA, TOF plus MTX dominated ADA+MTX but was extendedly dominated in the full 
incremental analysis. For cDMARD-IR patients with severe RA for whom MTX was contraindicated 
or not tolerated, TOF and TCZ monotherapy extendedly dominated ADA and ETN biosimilar 
regardless of the NMA used. The ICER of TCZ compared with TOF was £51,488 and £50,430 per 
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4$/< JDLQHG XVLQJ WKH FRPSDQ\¶V 10$ DQG XVLQJ WKH FODULILFDWLRQ 10$ KDYLQJ UHPRYHG WKH
constraint that TOF monotherapy had the same efficacy as TOF+MTX, respectively. 
In the bDMARD-IR patients with severe RA for whom RTX was an option, RTX plus MTX dominated 
TOF plus MTX regardless of the NMA used. Replacing TCZ plus MTX with TOF plus MTX after RTX 
plus MTX was estimated to result in ICERs of £67,852 and £90,846 SHU4$/<ORVWXVLQJWKHFRPSDQ\¶V
and the clarification NMA respectively. In the bDMARD-IR patients with severe RA for whom RTX 
was not an option, TOF plus MTX dominated GOL plus MTX regardless of the NMA used, and 
dominated ABT plus 07;DOVRZKHQXVLQJWKHFRPSDQ\¶V10$7KH,&(5RIETA biosimilar and 
TCZ in combination with MTX compared with TOF + MTX was higher than £30,000 per QALY gained 
regardless of the NMA used. Finally, in patients with moderate RA who are cDMARD-IR, the ICER 
of TOF plus MTX compared with MTX was £47,594 and £50,708 per QALY gained using the 
FRPSDQ\¶VDQGWKHFODULILFDWLRQ10$UHVSHFWLYHO\ 
3.4 Conclusions of the ERG Report 
The systematic review of clinical effectiveness showed TOF plus MTX to be superior to placebo plus 
F'0$5'LQWKHWDUJHWSRSXODWLRQDFURVVDQXPEHURIUHOHYDQWSULPDU\HQGSRLQWV7KHFRPSDQ\¶V10$
of clinical effectiveness showed that TOF plus cDMARD was superior to cDMARD and comparable 
to bDMARDs. Evidence to support the clinical effectiveness of TOF monotherapy in those who cannot 
tolerate MTX is less robust. The company presented results of analyses based on a de novo economic 
model. $FFRUGLQJWRWKHFRPSDQ\¶VDQDO\VHVTOF plus MTX dominates some of its comparators in 
cDMARD-IR and bDMARD-IR patients with severe RA who can tolerate MTX and for whom RTX is 
not an option. TOF monotherapy also dominates some of its comparators in cDMARD-IR patients with 
severe RA for whom MTX is contraindicated or not tolerated (no evidence exists for the relevant 
comparators in bDMARD-IR patents with severe RA who are MTX intolerant). In the cDMARD-IR 
population with moderate RA, the ICERs of TOF plus MTX versus MTX and TOF monotherapy versus 
cDMARDs are in excess of £47,000 per QALY gained. TOF plus MTX was dominated by RTX plus 
MTX. TKH(5*LGHQWLILHGDQXPEHURIOLPLWDWLRQVLQWKHFRPSDQ\¶VDQDO\VHV7he company addressed 
some of these limitations during the clarification round but the following issues remained: relevant 
comparators recommended by NICE were not included in the analyses; the NMA is subject to potential 
limitations; the company assumed equal efficacy for TOF as monotherapy and for TOF in combination 
with MTX; and, the company rounded modified HAQ-DI values to the nearest valid HAQ-DI score 
rather than allowing the valid HAQ-DI score to be sampled based on the continuous HAQ-DI value. 
The ERG undertook exploratory analyses alleviating these issues except for the first and providing 
results based on two alternative NMAs. The results of the exploratory analyses carried out by the ERG 
were slightly different to those presented by the company but did not significantly impact the 
conclusions. 
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4. Key Methodological Issues 
The main limitation of the amended economic analysis is the exclusion of relevant comparators from 
two of the six populations because of the lack of available evidence. The ERG believes that the analyses 
would have been improved by making assumptions on the efficacy of these comparators based on their 
relative efficacy on other populations and exploring the uncertainty in sensitivity analyses. The ERG 
notes WKDWWKHFRQFOXVLRQVRIWKHFRPSDQ\¶VDQDO\VHVWDOO\ZLWKWKHH[SHFWDWLRQVEHIRUHFRQVWUXFWLQJD
mathematical model, given the comparable efficacy and costs of the intervention to that of the 
comparators. The relative simplicity of this decision provides supportive evidence that abbreviated 
appraisals, which have been proposed by NICE,[35] can be delivered under conditions such as those in 
the TOF STA. 
5. National Institute for Health and Care Excellence Guidance  
In October 2017, on the basis of the evidence available (including verbal testimony of invited clinical 
experts and patient representatives), the NICE AC produced guidance that TOF in combination with 
MTX was recommended as an option for patients with severe RA whose disease has responded 
inadequately to intensive therapy with a combination of cDMARDS and also for patients with severe 
RA who have responded inadequately to, or who cannot have, other DMARDs, including at least 1 
bDMARD and where treatment with RTX plus MTX was not an option.  The AC also produced 
guidance that TOF monotherapy was recommended under the same criteria as TOF plus MTX, where 
RTX plus MTX was contraindicated or not tolerated. All recommendations were conditional on 
company providing TOF with the agreed PAS. 
5.1 Consideration of Clinical and Cost-Effectiveness Issues Included in the Final Appraisal 
Determination (FAD) 
This section summarises the key issues considered by the Appraisal Committee. The full list of the 
issues considered by the AC can be found in the FAD. [3] 
 
5.1.1 Current Clinical Management 
The AC considered the current clinical management of severe active RA following inadequate response 
to a TNFi in England and noted that the NICE guidance recommends BARI, CZP, ADA, ETA, IFX, 
ABA, TCZ and GOL (each with MTX) as options, when RTX (plus MTX) is contraindicated or not 
tolerated and ADA and ETA monotherapy as alternative options if RTX therapy cannot be given 
because MTX is contraindicated or not tolerated. The AC heard from clinical experts that responses to 
bDMARDs differ between patients and therefore it is important to have a range of options for bDMARD 
treatments. The AC was aware that the marketing authorisation covers the use of TOF in moderate to 
severe disease but that TA375[19] recommends that treatment with a bDMARD should only be started 
when disease is severe, that is a disease activity (DAS28) score of more than 5.1. 
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5.1.2 Uncertainties in the Clinical evidence 
The AC considered the problems highlighted by the ERG with the methods used in the company's NMA 
including different models for EULAR response in the 2 populations; a random effects model for 
patients DMARD-IR and a fixed effects model for patients whose disease responded bDMARD-IR; a 
uniform prior in the random effects model; using estimate 1 in their base case and the method of linking 
ETN to the network. Also, studies reporting EULAR responses were synthesised with converted 
EULAR response outcomes from studies that only reported ACR responses. At the clarification stage, 
the company corrected the errors in their network meta-analysis. The committee was satisfied that the 
corrected network meta-analysis was suitable for decision-making and showed that TOF works as well 
as bDMARDs. 
 
The AC heard from clinical experts that there is a need for new treatment options, particularly when 
there is an inadequate response to cDMARDs or bDMARDs. They also noted that there are subtly 
different AEs across the different classes of drugs for RA, but the AEs associated with Janus kinase 
inhibitors are unlikely to influence their desire to prescribe the drug. Both the clinical and patient experts 
highlighted that TOF is given orally, which has benefits for both patients and the health system. The 
patient experts emphasised that this is an important factor for patients who have difficulty injecting 
themselves because of the disease affecting their hands. 
 
5.1.3 Uncertainties in the Economic Modelling  
7KH$&FRQFOXGHGWKDWWKH(5*¶VDPHQGHGPRGHOZDVDGHTXDWHIRULWVGHFLVLRQ-making. For the 
bDMARD-IR patients who could receive RTX plus MTX, the AC noted the uncertainty on the 
incremental cost-effectiveness of the elongated sequence where TOF plus MTX was provided after 
RTX plus MTX. The AC concluded that TOF was not a cost-effective use of NHS resources in this 
population. The AC recognised the considerable uncertainty about the effectiveness of TOF 
monotherapy in bDMARD-IR patients but noted that in the appraisal of BARI,[36] the AC concluded 
that BARI monotherapy has similar clinical effectiveness to that of BARI in combination with 
cDMARDs. The AC concluded that its recommendations for TOF plus MTX should also apply to TOF 
monotherapy for bDMARD-IR patients with severe RA for whom MTX was contraindicated or not 
tolerated. 
6. Conclusions 
The evidence suggests that TOF plus MTX or as monotherapy has a similar efficacy for treating severe 
active RA following inadequate response to DMARD, to that of bDMARDs already recommended by 
NICE. Therefore, TOF plus MTX or as monotherapy was considered by NICE to be a cost-effective 
use of NHS resources for patients for whom RTX or MTX are contraindicated or not tolerated. 
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However, the cost of RTX treatment is significantly lower than that of TOF with comparable efficacy 
so TOF was not considered by NICE to be a cost-effective use of NHS resources when RTX and MTX 
is a treatment option for a patient. 
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